Currently out of the existing stock ratings of Matthew Caufield, 43 are a BUY (97.73%), 1 are a HOLD (2.27%).

Matthew Caufield

Work Performance Price Targets & Ratings Chart

Analyst Matthew Caufield works with a stock forecast success ratio of 12.96% fulfilled within 31.22 days on average. Previously, Matthew Caufield worked at HC WAINWRIGHT.

Matthew Caufield’s has documented 87 price targets and ratings displayed on 9 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on OCUP, Ocuphire Pharma at 13-May-2024.

Wall Street Analyst Matthew Caufield

Analyst best performing recommendations are on ISEE (IVERIC BIO).
The best stock recommendation documented was for GMTX (GEMINI THERAPEUTICS) at 12/15/2021. The price target of $20 was fulfilled within 34 days with a profit of $9.9 (33.11%) receiving and performance score of 9.74.

Average potential price target upside

ALDX Aldeyra The EYEN Eyenovia FDMT 4D Molecular Therapeutics  ISEE IVERIC bio OCUP Ocuphire Pharma OPT Opthea Ltd LYRA Lyra Therapeutics  UBX Unity Biotechnology GMTX Gemini Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

10

$6.09 (155.75%)

10

20 days ago

0/7 (0%)

$5.88 (142.72%)

Buy

8

$4.09 (104.60%)

25

7 months 9 days ago

0/10 (0%)

$6.16 (334.78%)

Hold

14

7 months 9 days ago

2/3 (66.67%)

$6.42 (84.70%)

362

Buy

2 years 4 months 29 days ago

0/1 (0%)

$9.48 (75.72%)

Buy

20

$16.09 (411.51%)

20

4 years 11 months ago

0/4 (0%)

$13.77 (221.03%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Matthew Caufield is most bullish on?

Potential upside of $18.24 has been obtained for OCUP (OCUPHIRE PHARMA)

Which stock is Matthew Caufield is most reserved on?

Potential downside of $6.09 has been obtained for ALDX (ALDEYRA THE)

What Year was the first public recommendation made by Matthew Caufield?

On 2020

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?